- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01150149
Evaluating Modes of Influenza Transmission Between Humans
Evaluating Modes of Influenza Transmission Using a Human Challenge/Exposure Model
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW1 0NH
- Retroscreen Virology Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 45 years, inclusive.
- Comprehension of the study requirements; availability for the required study period, ability to attend scheduled study visits, and willingness to participate in the inpatient challenge.
- Willingness to provide written consent for participation after reading the Subject Information Sheet and Informed Consent Form and after having adequate opportunity to discuss the study with an Investigator or qualified deputy.
- H3N2 antibody titre levels recorded as < 1:10
- Good general health status as determined by a screening evaluation no greater than 160 days prior to the quarantine challenge phase.
- Subjects shall be registered with a general practitioner who will confirm a subjects' past medical history and their suitability to participate based on this. Consent will be obtained to receive this information.
- For female subjects, provision of a history of reliable contraceptive practices [hysterectomy or bilateral tubal ligation, oral or implanted contraceptive use, intrauterine device, barrier method plus spermicide, history of a single male partner with vasectomy and documentary evidence confirming sterility (negative sperm counts at the recommended post-operative intervals) or a history of abstinence deemed credible by the Investigator]. The provision of this history does NOT replace the requirement to perform, and obtain negative results in, pregnancy tests.
Exclusion Criteria:
- Presence of any significant acute or chronic, uncontrolled medical or psychiatric illness, including but not exclusive to the conditions listed in Appendix 7, that in the view of the Investigator is associated with increased risk of complications of respiratory viral illness [subjects with uncomplicated chronic diagnoses stable and treated for 3 months (e.g. mild hypertension well-controlled with medication may be enrolled) provided the condition and its therapy are not known to be associated with an immunocompromised state or increased risk of complications of respiratory viral illness].
- Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of viral challenge. Healthcare workers who volunteer should not work with patients until 14 days after challenge or until their symptoms are fully resolved (whichever is the longer). Health care workers who work in units housing severely immunocompromised patients (e.g. bone marrow transplant units) will be excluded from the study.
- Venous access deemed inadequate for the phlebotomy demands of the study.
- Positive serologic tests for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- Evidence of drug abuse or a positive urine Class A drug or alcohol screen.
- Female subjects, who are known to be pregnant or who have a positive urine pregnancy test prior to challenge.
- Acute (within 7 days of challenge/exposure) or chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any nasopharyngeal complaint, or use of any intranasal medication for any indication (this includes any corticosteroid or beta agonist containing nasal spray).
- Any history during adulthood of asthma, chronic obstructive pulmonary disease or any other condition requiring bronchodilator therapy. A history of childhood asthma until and including the age of 12 is acceptable.
- Smokers unwilling/unable to desist for the quarantine phase duration of the study and any smoker who has a >10 pack year history of smoking. A nicotine test will be done at study specific screening and must be negative prior to admission to the quarantine unit.
- Subjects who have type I or type II Diabetes Mellitus.
- Body Mass Index > 30.
- An Abnormal ECG deemed clinically relevant by the Investigator.
- Any anatomic or neurologic abnormality impairing the gag reflex or conducive to aspiration, or history suggestive of such a problem or any abnormality significantly altering the anatomy of the nose or nasopharynx.
- Receipt of systemic glucocorticoids (in a dose 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within six months prior to challenge.
- Receipt of any investigational drug within 6 months prior to challenge, or prior participation in a clinical trial of any Influenza vaccine, or any investigational vaccine or experimental Influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge.
- History of adverse reaction to neuraminidase inhibitors e.g. oseltamivir
Presence of any febrile illness or symptoms of upper viral respiratory infection:
i. On the day of challenge/exposure or between admission for Influenza challenge/exposure and administration of the challenge inoculums (Donors) or exposure event (Recipients). Such subjects may be re-evaluated for enrollment in later studies after resolution of the illness; ii. Within 2 weeks prior to challenge or if challenge is set to occur during November, December, January, February, or March if there are any symptoms suggestive of viral respiratory infection occurring between screening and challenge.
- History of epistaxis (nose bleeds) more than 1 episode a month.
- Presence of household member or close contact (for an additional two weeks after discharge from the isolation facility) who is: (a) less than 3 years of age; (b) any person with any known immunodeficiency; (c) any person receiving immunosuppressant medications; (d) any person undergoing or soon to undergo cancer chemotherapy within 28 days of challenge; (e) any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition including but not exclusive to the conditions listed in Appendix 4; or (f) any person who has received a transplant (bone marrow or solid organ).
- Any laboratory test which is abnormal and which is deemed by the Investigator to be clinically significant. (This includes blood chemistry, haematology, cardiac iso-enzymes, or urinalysis).
- Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome.
- History of seasonal hay fever or a seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non prescription medication.
- As a result of the medical interview, physical exam, or screening investigations, the Investigator considers the subject unfit for the study.
- Those employed or immediate relatives of those employed at Retroscreen Virology Ltd or the study site.
- Staff and students working directly in or for any of the Units in which the principal or a co-Investigator works.
- Immediate relatives of any of the principal or co-Investigators.
- Receipt of a northern hemisphere seasonal influenza vaccine in the 2006/07/08 winter seasons.
- Receipt of any systemic cytotoxic chemotherapy agent at any time.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 1
|
|
Experimental: 2
No face touch
|
|
Experimental: 3
Surgical face mask
|
|
Experimental: 4
Surgical face mask + no face touch
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
One or more individuals who develop a symptomatic illness confirmed as influenza A
Time Frame: 24 hourly
|
24 hourly
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Van-Tam, MD, University of Nottingham
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08145
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on No face touch
-
Norwegian University of Science and TechnologySt. Olavs HospitalUnknownMyocardial IschemiaNorway
-
Federal University of São PauloUnknownCardiac Surgery | Aorta No-touchBrazil
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalTerminatedRadiofrequency Ablation | Microwave AblationKorea, Republic of
-
Örebro County CouncilCompletedAtherosclerosis | Ischemic Heart Disease
-
Uppsala UniversityActive, not recruitingIschemic Heart DiseaseDenmark, Sweden
-
Örebro County CouncilCompletedCoronary Artery DiseaseSweden
-
University of EdinburghChinese Academy of Medical Sciences, Fuwai HospitalCompletedAngina Pectoris | Blood Pressure | Coronary Heart Disease | Heart Rate VariabilityChina
-
Hasan Kalyoncu UniversityNot yet recruitingGaining the Role of Motherhood in Primipara Pregnancy (Focus)
-
Birmingham Women's NHS Foundation TrustCompletedHysteroscopy TechniqueUnited Kingdom
-
Southwest Hospital, ChinaUnknownHepatocellular CarcinomaChina